イバンドロン酸

関: ibandronate

WordNet

street name for lysergic acid diethylamide (同)back breaker, battery-acid, dose, dot, Elvis, loony toons, Lucy in the sky with diamonds, pane, superman, window pane, Zen
any of various water-soluble compounds having a sour taste and capable of turning litmus red and reacting with a base to form a salt
having the characteristics of an acid; "an acid reaction"

PrepTutorEJDIC

酸性の / 酸味のある,すっぱい(sour) / (言葉・態度などが)厳しい,しんらつな / 酸 / すっぱいもの / 《俗》=LSD

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/11/05 23:25:53」(JST)

wiki en

[Wiki en表示]

Ibandronic acid (INN) or ibandronate sodium (USAN) is a potent bisphosphonate drug developed by Hoffman La Roche and used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer.^[1] It may also be used to treat hypercalcemia (elevated blood calcium levels). Global sales in 2008 were 1.1B CHF ($1.0B USD at 01/01/2009 exchange rates).^[2]

Medical uses

Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women.^[3] In May 2003, the U.S. Food and Drug Administration (FDA) approved Ibandronate as a daily treatment for post-menopausal osteoporosis. The basis for this approval was a three-year, randomized, double-blind, placebo-controlled trial women with post-menopausal osteoporosis. Every participant also received daily oral doses of calcium and 400IUs [international units] of vitamin D. At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 percent when compared to the effects of the placebo drug.

Ibandronate is efficacious for the prevention of metastasis-related bone fractures in multiple myeloma, breast cancer, and certain other cancers.^[4]

Adverse effects

In 2008, the U.S Food and Drug Administration (FDA) issued a communication warning of the possibility of severe and sometimes incapacitating bone, joint and/or muscle pain.^[5] A study conducted by the American Society of Bone and Mineral Research concluded that long term use of bisphosphonates, including Boniva, may increase the risk of a rare but serious fracture of the femur. ^[6]

Brand names

Ibandronic acid is marketed under the trade names Boniva in the USA, Bondronat in Europe, Bonviva in Asia,Ibandrix in Ecuador and Bondrova in Pakistan.

References

^ Bauss F, Schimmer RC (March 2006). "Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis". Therapeutics and clinical risk management 2 (1): 3–18. PMC 1661644. PMID 18360577.
^ "Roche 2008 Annual Report" (PDF). Roche. Retrieved 2009-08-13.
^ "boniva". The American Society of Health-System Pharmacists. Retrieved 3 April 2011.
^ Sittig HB (2012). "Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer: focus on ibandronate". Onkologie 35 (6): 380–7. doi:10.1159/000338947. PMID 22722461.
^ "Information for Healthcare Professionals: Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa)". U.S. Food and Drug Administration. Retrieved 27 October 2010.
^ "Drugs Commonly Prescribed for Osteoporosis Patients are Effective at Reducing Risk of Hip and Spine Fractures, But Panel Says May be Related to Unusual Thigh Bone Fractures When Used Long Term". Journal of Bone and Mineral Research=27 October 2010.

External links

Ibandronate bound to proteins in the PDB
Boniva Osteoporosis Treatment by GlaxoSmithKline and Roche Laboratories
Boniva adverse events reported to the FDA

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 閉経後女性における骨粗鬆症に対するビスホスホネート投与 the use of bisphosphonates in postmenopausal women with osteoporosis
2. 多発性骨髄腫患者のビスフォスフォネート製剤の使用 the use of bisphosphonates in patients with multiple myeloma
3. 高カルシウム血症の治療 treatment of hypercalcemia
4. 早期乳癌における骨吸収抑制剤の使用の概要 overview of the use of osteoclast inhibitors in early breast cancer
5. 骨粗鬆症の予防 prevention of osteoporosis

English Journal

Liquid chromatography-mass spectrometry analysis of five bisphosphonates in equine urine and plasma.

Wong AS1, Ho EN2, Wan TS3, Lam KK4, Stewart BD4.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.J Chromatogr B Analyt Technol Biomed Life Sci.2015 Aug 15;998-999:1-7. doi: 10.1016/j.jchromb.2015.06.020. Epub 2015 Jun 20.
Bisphosphonates are used in the management of skeletal disorder in humans and horses, with tiludronic acid being the first licensed veterinary medicine in the treatment of lameness associated with degenerative joint disease. Bisphosphonates are prohibited in horseracing according to Article 6 of the
PMID 26143477

Implant Placement Adjacent to Successfully Treated Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ).

Rugani P1, Kirnbauer B1, Acham S1, Truschnegg A1, Jakse N1.
The Journal of oral implantology.J Oral Implantol.2015 Jul;41 Spec No:377-81. doi: 10.1563/AAID-JOI-D-13-00178. Epub 2014 Mar 4.
PMID 24593250

Dose-Effectiveness Relationships Determining the Efficacy of Ibandronate for Management of Osteoporosis: A Meta-Analysis.

Hou Y1, Gu K, Xu C, Ding H, Liu C, Tuoheti Y.
Medicine.Medicine (Baltimore).2015 Jul;94(26):e1007. doi: 10.1097/MD.0000000000001007.
The purpose of this study was to perform a meta-analysis on the efficacy of ibandronate by evaluating the effect sizes of different dosing regimens.Major electronic databases were searched from 1985 to February 2015. A random effects meta-analysis was performed in STATA.Data from 34 studies (13,639
PMID 26131800

Related Pictures

★リンクテーブル★

リンク元

「イバンドロン酸」

Ibandronic acid
Systematic (IUPAC) name
	{1-Hydroxy-3-[methyl(pentyl)amino]propane-1,1-diyl}bis(phosphonic acid)
Clinical data
AHFS/Drugs.com	International Drug Names
Licence data	EMA:Link, US FDA:link
Pregnancy; category	US: C (Risk not ruled out);
Legal status	℞ (Prescription only);
Routes of; administration	Oral, intravenous
Pharmacokinetic data
Bioavailability	0.6%
Protein binding	90.9 to 99.5%; (concentration-dependent)
Metabolism	Nil
Biological half-life	10 to 60 hours
Excretion	Renal
Identifiers
CAS Registry Number	114084-78-5
ATC code	M05BA06
PubChem	CID: 60852
IUPHAR/BPS	3059
DrugBank	DB00710
ChemSpider	54839
UNII	UMD7G2653W
KEGG	D08056
ChEMBL	CHEMBL997
Chemical data
Formula	C9H23NO7P2
Molecular mass	319.229 g/mol
	SMILES O=P(O)(O)C(O)(CCN(CCCCC)C)P(=O)(O)O ;
	InChI InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17) ; Key:MPBVHIBUJCELCL-UHFFFAOYSA-N ;
(what is this?) (verify)

　　[★]

英: ibandronate、ibandronic acid
同: イバンドロネート
化: イバンドロン酸ナトリウム水和物
商: ボンビバ
関: 骨粗鬆症治療薬

骨粗鬆症治療薬;ビスホスホネート系;窒素含有

[pmid18360577-1] Bauss F, Schimmer RC (March 2006). "Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis". Therapeutics and clinical risk management 2 (1): 3–18. PMC 1661644. PMID 18360577.

[2] "Roche 2008 Annual Report" (PDF). Roche. Retrieved 2009-08-13.

[AHFS-3] "boniva". The American Society of Health-System Pharmacists. Retrieved 3 April 2011.

[4] Sittig HB (2012). "Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer: focus on ibandronate". Onkologie 35 (6): 380–7. doi:10.1159/000338947. PMID 22722461.

[5] "Information for Healthcare Professionals: Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa)". U.S. Food and Drug Administration. Retrieved 27 October 2010.

[6] "Drugs Commonly Prescribed for Osteoporosis Patients are Effective at Reducing Risk of Hip and Spine Fractures, But Panel Says May be Related to Unusual Thigh Bone Fractures When Used Long Term". Journal of Bone and Mineral Research=27 October 2010.

匿名

検索

案内

案内

ibandronic acid